Pharmaceutical 99% Raw Powder Abiraterone for Treatment Prostatic Cancer

• Model NO.: 841205-47-8
• Customized: Non-Customized
• Suitable for: Adult
• Purity: >99%
• CAS No: 154229-19-3
• MW: 349.51
• Grade: Pharma Grade
• Delivery Time: 5-7 Days
• Transport Package: Discreet Package
• Origin: China

• Powder: Yes
• Certification: HSE, ISO 9001, USP, BP
• State: Solid
• Synonym: Abiraterone
• Mf: C24h31no
• Appearance: White Powder
• Usage: Treatment of Prostatic Cancer.
• Trademark: Saichuang
• Specification: Enterprise standard

Pharmaceutical 99% Raw Powder Abiraterone For Treatment Prostatic Cancer

Description of Active Pharmaceutical Ingredients Abiraterone:
 
(1) Abiraterone is a new type of hormone therapy. It is also called abiraterone acetate. It is used to treat prostate cancer that has spread to other parts of the body. It may help some men to live longer. It can also help control symptoms. Clinical trials are also using abiraterone for earlier stages of prostate cancer and advanced breast cancer. Abiraterone is associated with a not uncommon rate of serum enzyme elevation during therapy, but has not been clearly linked to cases of clinically apparent liver injury with jaundice.
 
(2) Abiraterone is a steoridal compound with antiandrogen activity. it is a Cytochrome P450 17A1 Inhibitor. The mechanism of action of abiraterone is as a Cytochrome P450 17A1 Inhibitor, and Cytochrome P450 2D6 Inhibitor, and Cytochrome P450 2C8 Inhibitor that catalyzes the 17alpha-hydroxylation of intermediates involved in synthesis. Administration of this agent may suppress production by both the testes and the adrenals to castrate-range levels.

 
Medical Usage for Active Pharmaceutical Ingredients Abiraterone:
 
(1) Abiraterone, a steoridal cytochrome P 450 17alpha-hydroxylase-17,20-lyase inhibitor (CYP17), is currently undergoing phase II clinical trials as a potential drug for the treatment of androgen-dependent pr ostate cancer.
 
(2) Currently, for patients of advanced prostate cancer, androgen deprivation therapy including drugs and surgery is generally the preferred method of including drugs and surgery in order to reduce the testicular androgen synthesis. However, this treatment can't suppress other parts of the body for yielding the male hormone.

(3) Abiraterone is a therapeutic agent for prostate cancer with the English name for Abiraterone. It is developed by researchers coming from the British Royal Marsden Hospital located in southwest (world-renowned cancer research treatment center). It is kind of drug which is able to repress any part of the body for androgen production. It can not only reduce the levels of the prostate-specific antigen (PSA) which represents the tumor activity, but also helps to shrink the tumor. It can also apply to cancer patients who have been subject to chemotherapy in the past, revealing treatment hope.
 
(4)Abiraterone acetate is indicated for use in combination with prednison as a treatment for metastatic castration-resistant prostate cancer. In Australia it is covered by the Pharmaceutical Benefits Scheme when being used to treat castration-resistant prostate cancer and given in combination with (subject to the conditions that the patient is not currently receiving chemotherapy, is either resistant or intolerant of docetaxel, has a WHO performance status of <2, and his disease has not since become progressive since treatment with PBS-subsidised abiraterone acetate has commenced).


Mechanism of action:

Abiraterone, the active metabolite of abiraterone acetate, inhibits CYP17A1, which manifests as two enzymes, 17-hydroxylase (IC50 = 2.5 nM) and 17,20-lyase (IC50 = 15 nM) (six-fold more selective for inhibition of 17-hydroxylase over 17,20-lyase) that are expressed in testicular, adrenal, and prostatic tumor tissues. CYP17 catalyzes two sequential reactions: (a) the conversion of pregnenolone and progesterone to their 17-hydroxy derivatives by its 17-hydroxylase activity, and (b) the subsequent formation and respectively, by its 17,20-lyase activity.

Abiraterone also acts as a partial antagonist of androgen receptors, and as an inhibitor of the enzymes 3β-hydroxysteorid dehydrogenase,CYP11B1 (steorid 11β-hydroxylase), and other CYP450s (e.g., CYP1A2, CYP2C9, and CYP3A4).


Abiraterone acetate Function:

Abiraterone is a drug used in castration-resistant prostate cancer. It is formulated as the prodrug abiraterone acetate. Abiraterone can be used as a prostate cancer drug treatment. Abiraterone is a inhibitor of CYP17. It can be used to treat CRPC.


Abiraterone acetate dose and schedule:

The recommended dose and schedule for abiraterone acetate is 1000 mg orally once daily in combination with prednison 5 mg orally twice daily. Abiraterone acetate should be taken on an empty stomach. No food should be consumed for at least two hours before the dose of abiraterone acetate is taken and for at least one hour after the abiraterone acetate dose.
 

Payment And Express:



Advantage:

1,High quality with competitive price
1)Standard: Enterprise Standard
2)All Purity≥99%
3)We are manufacturer and can provide high quality products with factory price.

2,Fast and safe delivery
1)Parcel can be sent out in 24 hours after payment. Tracking number available
2)Secure and discreet shipment. Various transportation methods for your choice.
3)Customs pass rate ≥99%
4)We have our own agent/remailer/distributor who can help us ship our products very fast and safe, and we have stock in there for transferring.

3,We have clients throughout the world.
1)Professional service and rich experience make customers feel at ease, adequate stock and fast delivery meet their desire.
2)Market feedback and goods feedback will be appreciated, meeting customers's requirement is our responsibility.
3)High quality,competitive price,fast delivery ,first-class service gain the trust and praise from the customers.